Table 1.
Clinical and radiologic features of the five intracranial DSRCTs within our series. Available clinical and radiologic information, including the status at last follow‐up and length of follow‐up interval, is depicted. The Memorial Sloan Kettering Cancer Center (MSKCC) P6 protocol has seven courses of chemotherapy. Courses 1, 2, 3 and 6 included cyclophosphamide 4200 mg/m2, doxorubicin 75 mg/m2 and vincristine. Courses 4, 5 and 7 consisted of ifosfamide 9 g/m2 and etoposide 500 mg/m2 for previously untreated patients 34. The symbol “–” is used to indicate when selected information was not available. Abbreviations: XRT = radiation therapy; Gy = gray; MSKCC = Memorial Sloan Kettering Cancer Center.
| Case # | Age (years) | Gender | Tumor location | Size (cm) | Presenting symptoms | Imaging findings at presentation | Extent of resection | Adjuvant chemotherapy | Adjuvant radiation therapy | Clinical status | Length of follow‐up |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 13 | M | Right temporal | 4.3 | Seizures | Solid and cystic mass, heterogeneous nodular enhancement | Gross total | None | 6 weeks of radiation therapy (XRT) | No evidence of disease | 16 months |
| 2 | 6 | M | Left occipital | 6.3 | – | Heterogeneous mass (contrast not administered) | – | – | – | – | – |
| 3 | 25 | M | Left cerebellum | 4.7 | Left hand numbness, headaches | Heterogeneous mass, minimal nodular enhancement | Gross total | None | None | Deceased | 1 month |
| 4 | 11 | M | Left parietal | 8.5 | Progressive right‐sided weakness | Multilocular cystic mass with enhancing nodules | Gross total | 6 cycles of vincristine and cyclophosphamide | XRT, 55.8 Gy in 31 fractions | no evidence of disease | 13 months |
| 5 | 8 | M | Right frontal | – | Headaches | T1 hyperintense cystic mass with focal enhancement | Gross total | MSKCC P6 protocol | XRT, 55.8 Gy with a daily fraction of 1.8 Gy | no evidence of disease | 8 years |